Sildenafil Citrate
Phase 2
Sildenafil Citrate is one of 39 therapeutic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
120 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Lunsekimig
SanofiPhase 3
Tozorakimab
AstraZenecaPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Astegolimab
RochePhase 3
Titrated Oxygen
RRigshospitalet, Denmark
Phase 3
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Birth Asphyxia1 trial
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia: An Open-label Dose-finding Clinical Trial (Phase Ib Study)
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 1·NCT04169191·20 enrolled
Spinal Cord Injuries1 trial
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
Active, not recruiting·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT04565925·24 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Sildenafil Citrate. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Alberta